a2025june-contextxcorpde

June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “plan”, “predict”, “expect”, “estimate”, “anticipate”, “intend”, “goal”, “strategy”, “believe”, “could”, “would”, “potential”, “project”, “continue” and similar expressions and variations thereof. Forward-looking statements may include statements regarding the Company’s business strategy, cash flows and funding status, potential growth opportunities, clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. Any forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in documents the Company has filed with the SEC. Any forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. This presentation discusses product candidates that are under preclinical and clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. While the Company believes its internal research is reliable, such research has not been verified by any independent source. All the scientific, preclinical and clinical data presented within this presentation are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Forward Looking Statement Executive Summary Context Therapeutics Inc. - June 20252

Building a T cell Engager Pipeline Executive Summary Context Therapeutics Inc. - June 20253 TCEs are Gaining Momentum Recent TCE clinical data demonstrates promising efficacy and safety in solid tumors • Clinical activity across a broad range of targets, including Claudin 18.2, DLL3, gp100, PSMA, and STEAP1 • Responses in “cold” tumors, including neuroendocrine, pancreatic, prostate, and small cell lung cancer • Promising safety with low rate of Grade ≥ 3 cytokine release syndrome (CRS) Potentially Best-in-Class Assets CTIM-76: Claudin 6 (CLDN6) x CD3 bispecific antibody • CLDN6 is overexpressed in ovarian, endometrial, lung, and other solid tumors • CTIM-76 was designed to bind selectively to CLDN6 over similar claudin family members, including CLDN3/4/9 CT-95: Mesothelin (MSLN) x CD3 bispecific antibody • MSLN is overexpressed in ovarian, pancreatic, lung, and other solid tumors • CT-95 was designed to bind selectively to membrane-bound MSLN to enhance drug exposure and activity CT-202: Nectin-4 x CD3 bispecific antibody • Nectin-4 is overexpressed in bladder, breast, lung, and other solid tumors • CT-202 was designed to be conditionally active within the tumor microenvironment Well Capitalized Strong financial position with high quality investor base • Anticipated cash runway into 2027

Executive Summary Pipeline Overview Context Therapeutics Inc. - June 20254 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) DISCOVERY DEVELOPMENT PHASE 1 PHASE 2 RECENT & ANTICIPATED MILESTONES CTIM-76 Claudin 6 (CLDN6) > 50,000 patients Phase 1 first patient dosed January 2025 Initial data 1H 2026 CT-95 Mesothelin (MSLN) > 100,000 patients Phase 1 first patient dosed April 2025 Initial data Mid 2026 CT-202 Nectin-4 > 125,000 patients IND filing Mid 2026 CTIM-76: CLDN6 x CD3 CT-95: MSLN x CD3 Product differentiation: highly selective for CLDN6 over CLDN3/4/9 Safety: potent CD3 induction without broad cytokine activation Cancer Indications: ovarian, endometrial, lung, testicular α-CLDN6 Fab α-CD3 scFv α-MSLN Fab α-CD3 scFv CT-202: Nectin-4 x CD3 Product differentiation: avidity optimized to avoid mesothelin (MSLN) fragments Safety: sterically hindered CD3 to avoid T cell crosslinking Cancer indications: lung, pancreatic, ovarian, mesothelioma α-Nectin-4 Fab α-CD3 scFv Product differentiation: conditionally activate in the tumor microenvironment Safety: sterically hindered CD3 to avoid T cell crosslinking Cancer indications: bladder, colon, breast

T Cell Engager Strategy Context Therapeut ics Inc . - June 20255

T Cell Engaging (TCE) Bispecific Antibodies TCEs are engineered to activate an immune response against cancer cells T Cell Engager Strategy Context Therapeutics Inc. - June 20256 Mechanism of Action T cell engagers (TCEs) are antibodies engineered to redirect the immune system’s T cells to recognize and kill cancer cells TCE bind to a target antigen expressed on a cancer cell and to an immune activator on T cells, such as CD3 This mechanism allows for the direct activation of T cells and their anti-tumor features, ultimately resulting in the killing of cancer cells TCE Bispecific Antibody T Cell Cancer Cell Target Antigen CD3 Cancer Cell Killing

Realizing the Full Potential of T Cell Engagers (TCE) 2024 was a watershed year for TCEs T Cell Engager Strategy Context Therapeutics Inc. - June 20257 $680M ACQUISITION Confirmed response rate of 35% (11/31) across all tumor types (SCLC and other neuroendocrine tumors), including three complete responses Generally well tolerated with no dose limiting toxicities at target doses1 HPN328 (DLL3) +$1.6B APPRECIATION 83% (5/6) of JANX007 patients achieved PSA50 declines with first step dose ≥ 0.2mg and 56% (10/18) patients achieved PSA50 declines with the first dose ≥ 0.1mg Early JANX008 data presented one confirmed PR and no CRS greater than Grade 1 in any cohort2 JANX007 / JANX008 (PSMA / EGFR) $1B+ PEAK SALES OPPORTUNITY At 10mg, mPFS was 4.9 months with mOS of 14.3 months across 100 patients with small cell lung cancer (SCLC) Granted Accelerated FDA Approval in May 20243 Tarlatamab / IMDELLTRATM (DLL3) 1 Merck Press Release 8 Jan 2024; 2 Janux Press Release 26 Feb 2024; 3 Amgen Press Release 16 May 2024; 4 Daiichi Sankyo Press Release 6 Aug 2024; 5 Medilink Therapeutics Press Release 8 Oct 2024; 6 Marengo Therapeutics Press Release 13 Sept 2024. Information provided is for illustrative purposes only, is not indicative of future performance, and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. TCE + ADC Clinical Trial Partnerships DLL3 TCE + B7-H3 ADC4 TCR Vβ TCE + TROP2 ADC6 DLL3 TCE + B7-H3 ADC5

TCE Activity in “Cold” Tumors Tumor shrinkage with low rate of Grade ≥ 3 cytokine release syndrome (CRS) Asset Tarlatamab (AMG757) HPN328 IBI389 JANX007 VIR-5500 JNJ-78278343 Xaluritamig (AMG509) Ubamatamab (REGN4018) Target x Effector DLL3 x CD3 DLL3 x CD3 CLDN18.2 x CD3 PSMA x CD3 PSMA x CD3 KLK2 x CD3 STEAP1 x CD3 MUC16 x CD3 Cancer Indication Small Cell Lung Small Cell Lung Pancreatic Prostate Prostate Prostate Prostate Ovarian Normal tissue expression Brain Brain Gastrointestinal (GI) Endocrine, GI, pancreas, skin, marrow Endocrine, GI, pancreas, skin, marrow Limited Brain, respiratory, prostate, smooth muscle Respiratory Patients (n) 100 19 27 16 12 (1st dose >120 µg/kg) 45 21 13 Efficacy ORR: 40% PFS: 4.9 months ORR: 32% ORR: 38% PSA50: 100% PSA90: 63% ORR: 50% PSA50: 58% PSA90: 9% PSA50: 42% PSA50: 50% PSA90: 28% ORR: 20% ORR: 31% Grade ≥ 3 CRS 1% 3% 0% 6% 0% 0% 2% 0% Reference Ahn 2023 ESMO 2023 ASCO 2024 15 Nov 2024 data cutoff 13 Nov 2024 data cutoff ASCO 2025 ESMO 2024 ESMO 2022 T Cell Engager Strategy Context Therapeutics Inc. - June 20258 Information provided in the table above as of June 2, 2025. Information provided is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

Context’s TCE ApproachHistorical TCE Challenges Context’s Approach to TCEs T Cell Engager Strategy Context Therapeutics Inc. - June 20259 Cytokine release syndrome Weak clinical activity Poor durability Premedication + step-dosing High affinity CD3 binding Combination with ADC or Checkpoint ✘ ✘ ✘ Broadly expressed antigens Tumor restricted antigens ✘

CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - June 202510

CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CTIM-76 Program 11 Context Therapeutics Inc. - June 2025 Initial indications of interest based on: • CLDN6 prevalence • Patient population size • Observed clinical responses • Potential accelerated pathway Selected Cancer indications Incidence (US Only) R/R Incidence CLDN6 Positive CLDN6 Med/High Patient Population Based on R/R Incidence Endometrial 65,900 14,000 51%1 22%1 7,140 Ovarian 19,900 12,800 44%1 25%1 5,632 Testicular 9,910 400 94%1 90%1 376 Non-Small Cell Lung 201,229 110,653 26%1 6%1 28,769 Colon 152,810 53,010 40%2 0%2 21,204 Breast 290,600 43,800 40%2 0%2 9,417 Sarcoma 17,100 12,390 20%2 10%2 2,478 Gastric 26,380 11,090 9%1 7%1 998 1 Context internal data; 2 Mackensen, Nature Medicine, 2023. Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; CLDN6 target prevalence is based on IHC or RNAseq from published reports. Patient population derived from midpoint of CLDN6 positive population multiplied by R/R incident population.

CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression across many solid tumors CTIM-76 Program Context Therapeutics Inc. - June 202512 Oncofetal Characteristics of CLDN6 Huan, Mol Med Reports, 2021

Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - June 202513 • CLDN6 antigen is conformationally dependent, which limits access to antibody-antigen binding • Antigen binding region is highly conserved with CLDN3, CLDN4, and CLDN9, making CLDN6- selective binding a challenge1 • CLDN6 selectivity is required to avoid off-target liabilities identified in murine knockout and knockdown studies with CLDN3 (intestine)2, CLDN4 (liver, pancreas)3, and CLDN9 (liver, ear)4 1 Screnci, Cancer Res, 2022; 2 Tanaka, J Hepatol, 2018; 3 Cordat, Physiology, 2019; Li, FEBS Open Bio, 2020; 4 Nakano, PLoS Genet, 2009 Human CLDN Family Tree

CLDN6 Target Validation via ADC and CAR-T CTIM-76 is designed to potentially address limitations of TORL-1-23 (ADC) and BNT211 (CAR-T) CTIM-76 Program Context Therapeutics Inc. - June 202514 CTIM-76 Addresses Limitations of ADC and CAR-THigh Response Rates with CLDN6 ADC and CAR-T CTIM-76 BNT2111 TORL-1-232,3 High Potency Low Expression Cutoff Scalable manufacturing IHC Cutoff = 50% 2+/3+ staining IHC Cutoff = >30% 1+ staining Basket1 51% ORR (n=17/33) Ovarian Cancer2 45% ORR (n=9/20) Testicular Cancer1 41% ORR (n=5/12) Ovarian Cancer1 58% ORR (n=7/12) CTIM-76 is ~50-100x more potent than TORL-1-23 CTIM-76 targets low / med / high CLDN6 expressing cells Basket2 33% ORR (n=15/45) Lung Cancer1 1 partial response 1 Haanen, ESMO 2024; 2 Konecny, ESMO 2024; 3 Context SITC 2023. Information provided is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T cell activation • Silenced Fc domain to avoid off target immune cell activation Potentially wide therapeutic window • T cell dependent cellular cytotoxicity with no or minimal activation of circulating cytokines • Humanized CLDN6 and CD3 binding domains Ease of manufacturing • IgG1 backbone is highly stable and enables high yield CTIM-76 Program Context Therapeutics Inc. - June 202515 α-CLDN6 Fab α-CD3 scFv IgG1 backbone Silenced Fc Phase 1 first patient dosed in January 2025

CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - June 202516 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HEK-293F cells >10,000x • Potency assay provides a better assessment for a TCE bispecific than binding assays for off-target liabilities associated with CLDN3, CLDN4, or CLDN9 • CTIM-76 CLDN6 EC50 of 0.0004 nM (cytotoxicity) • CTIM-76 preferentially targets CLDN6, with minimal binding and cytotoxicity against CLDN9-expressing cells >500x 0 150 300 450 600 0 7 14 21 Tu m or V ol um e (m m 3) Day Vehicle 0.01mg/kg 0.1mg/kg 1.0mg/kg Tumor Regression • CTIM-76 effectively engaged systemically administered human PBMC cells to promote significant tumor regression and complete responses in OVCAR3 (~96,000 CLDN6 copies per cell) ovarian xenograft models in mice • CTIM-76 was well tolerated in OVCAR3 xenograft study • NSG-b2m knockout mice (n=14/arm) engrafted with human PBMCs and bearing advanced subcutaneous OVCAR3 tumor xenografts were treated twice per week

CTIM-76 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06515613) • Target population ̶ Platinum resistant ovarian cancer ̶ Endometrial and testicular cancer relapsed to standard of care ̶ CLDN6+ positive (10% ≥ 1+) • Trial objectives ̶ Assess safety and tolerability at increasing dose levels ̶ Pharmacokinetic and pharmacodynamic data ̶ Evaluate preliminary anti-tumor activity • Dosing and Administration ̶ Weekly IV infusion starting at 22.5 µg, corresponding to MABEL dose ̶ Premedication (steroid + NSAID) and step dosing to manage cytokine release syndrome (CRS) • Trial Status ̶ Dosing cohort 3 (70 µg prime + 140 µg full dose) ̶ 7 active sites in the United States CTIM-76 Program 17 Single patient (Cohorts 1 and 2) Step Dose Escalation: 3 + 3 design (3-6 patients per cohort) MTD or RP2D Cancer type to be selected based upon Dose Escalation data; Two doses to be evaluated Any ≥ Grade 2 AE Part 2 – Dose Expansion / Optimization (~30 patients) Part 1 – Dose Escalation (~40 patients) Context Therapeutics Inc. - June 2025 Trial status information provided as of June 2, 2025. MABEL = minimum anticipated biological effect level; MTD = maximum tolerated dose; RP2D = recommended Phase 2 dose

CTIM-76 Competitive Landscape CLDN6 T Cell Engaging Bispecifics Clinical Programs Discontinued CTIM-76 XmAb541 ARC101 SAIL66 AMG794 Company Context Xencor Third Arc Chugai Amgen Stage Ph 1 Ph 1 Ph 1 Ph 1 Ph 1 (Discontinued July 2024)1 Bispecific Format 1 + 1 2 + 1 1 + 1 Dual Specific Fab HLE Bite CLDN6 Selectivity High1 Moderate2 High3 Moderate4 High5 Preclinical Tolerability Well tolerated Well tolerated Well tolerated Poor tolerability Poor tolerability Immune Effector CD3 CD3 CD3 CD3 / 4-1BB CD3 CTIM-76 Program 18 Clinical trials.gov accessed on June 2, 2025 1 Rucker, SITC 2023 2 Faber, AACR 2021; Patent US11739144; 3 AACR 2025; 4 Kamikawa, SITC 2023; Patent WO2021006328 5 Patent WO2022096700. N.D.= not disclosed. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.Context Therapeutics Inc. - June 2025

CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - June 202519

MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-95 Program 20 Context Therapeutics Inc. - June 2025 Selected Cancer indications Incidence (US Only) R/R Incidence MSLN Positive MSLN Med/High Patient Population Based on R/R Incidence Non-Small Cell Lung 201,229 110,653 55% 36% 60,859 Pancreatic 66,440 51,750 80% 61% 41,400 Ovarian 19,900 12,800 90% 80% 11,520 Mesothelioma 3,000 2,500 70% 60% 1,750 Colon 152,810 53,010 41% 17% 21,734 Esophageal 22,370 16,130 41% 26% 6,613 Endometrial 65,900 14,000 45% 23% 6,300 Gastric 26,380 11,090 49% 23% 5,434 Breast (TNBC) 62,054 15,500 30% 18% 4,650 Cervical 13,820 4,360 42% 21% 1,831 Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; MSLN target prevalence is based on Simon et al, Biomedicines, 2021. Patient population derived from MSLN positive population multiplied by R/R incident population. Initial indications of interest based on: • MSLN prevalence • Patient population size • Potential accelerated pathway

Mesothelin (MSLN) Target Validation via ADC and CAR-T CT-95 has the potential to be used after RC88 and HBM-9033, or in combination CT-95 Program 21 Context Therapeutics Inc. - June 2025 CT-95 Use CaseRecent Investor and Strategic Interest in MSLN December 2023 Pfizer licensed ex-Asia rights to HBM-9033 for $53 million upfront and up to $1.05 billion in milestone payments June 2024 Phase 1 data in MSLN-high for RC881: • 45% ORR in platinum-resistant ovarian cancer • 33% ORR in cervical cancer • 31% ORR in non-small cell lung cancer August 2024 $144 million Series B financing led by RA Capital to fund OPB-101 lead MSLN CAR-T Target validation via RC88 (ADC) in MSLN-high population ADC treatment debulks tumor, resulting in clonal selection for low/medium MSLN cells TCE is ~50-100x more potent than ADC, making it ideally suited to treat low/medium expressors Potential to be used as a monotherapy or in combination with MSLN ADC or FRα ADC TCE and ADC have non-overlapping mechanisms of action, safety, and resistance mechanisms 1 Remegen Biosciences, Press Release, 3 June 2024. Information provided is for illustrative purposes and is not indicative of future performance.

MSLN Target Biology Shed mesothelin (sMSLN) in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - June 202522 MSLN is bound to tumor cells via a GPI-anchor Like many GPI-anchored proteins, MSLN can be cut into smaller fragments1,2 The MSLN gene encodes a precursor that is cleaved into two products: a soluble N-terminal protein called megakaryocyte potentiating factor (MPF), and a membrane-bound fragment called full length mesothelin (FL-MSLN) sMSLN serves as a competitive sink, preventing antibodies from binding to the tumor, which can lead to suboptimal drug exposure and efficacy Overcoming Fragmented MSLN in the Tumor Microenvironment 1 Zhang, Transl Oncol, 2022; 2 Liu, Commun Biol, 2020; GPI = Glycosylphosphatidylinositol Precursor MSLN Protein FL-MSLNMPF Tumor Cell Enzymatic cleavage GPI sMSLN fragments Enzymatic cleavage

CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN epitope • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crosslinking by shed MSLN, mitigating off-tumor T cell activation • Cooperative binding of MSLN on tumor surface crosslinks CD3, activating T cells Ease of manufacturing • IgG1 backbone is highly stable and enables high yield • Drug product ready for Phase 1 trial CT-95 Program Context Therapeutics Inc. - June 202523 α-MSLN Fab α-CD3 scFv IgG1 backbone Silenced Fc Phase 1 first patient dosed in April 2025

Two-Pronged Approach to Overcoming Soluble MSLN Sink Challenge CT-95 Program 24 Binds MSLN Epitope Close to Cell Surface Activates T cells Through Cooperative Binding + CD3 Potent T cell activationNo T cell activation No crosslinking with shed MSLN MSLN on tumor crosslinks CD3Far From cell surface Close To cell surface Amatuximab MORAb-009 mAb Anetumab BAY 94-9343 ADC CT-95 Binds membrane- proximal epitope T cell Tumor Context Therapeutics Inc. - June 2025

Low MSLN Expression 4k copies per cell Medium MSLN Expression 27k copies per cell CT-95 Intended to Overcome MSLN Sink HPN-536 (Harpoon Therapeutics) binds to MSLN fragments in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - June 202525 CT-95 +10nM MSLN +30nM MSLN CT-95 +10nM MSLN +30nM MSLN HPN-536 +10nM MSLN +30nM MSLN HPN-536 +10nM MSLN +30nM MSLN HPN-536 clones are not derived from the original manufacturer and were produced for this research study based on the published sequence of their antibody variable chains; thus, the clones used in this study are biosimilars and may not be identical to the antibodies formulated for clinical development.

CT-95 is Highly Active and Well Tolerated Across In Vivo Models Complete tumor regressions in mice at doses ≤ 0.05 mg/kg CT-95 Program Context Therapeutics Inc. - June 202526 Primary Lesion Model Metastatic Lesion Model OVCAR3 pre-passaged in mice to generate aggressive, metastatic tumor model Ovarian cancer line OVCAR3 flank implantation tumor model Vehicle Control CT-95 0.05 mg/kg Day 1 Day 70

CT-95 Phase 1 Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06756035) • Target population ̶ Platinum resistant ovarian cancer ̶ Mesothelioma, Pancreatic, Colorectal, NSCLC adenocarcinoma, Cholangiocarcinoma, others • Biomarker stratification ̶ Due to high MSLN prevalence, ovarian and pancreatic cancers and mesothelioma epithelioid subtype do not require prospective screening ̶ All other indications require prospective MSLN screening via IHC • Trial objectives ̶ Assess safety and tolerability at increasing dose levels ̶ Pharmacokinetic and pharmacodynamic data ̶ Evaluate preliminary anti-tumor activity • Trial Status ̶ Dose escalation is ongoing ̶ 2 active sites in the United States CT-95 Program 27 Context Therapeutics Inc. - June 2025 Single patient (Cohorts 1 and 2) Step Dose Escalation: Bayesian Optimal Interval (BOIN) MTD or RP2D Cancer type(s) to be selected based upon Dose Escalation data; Two doses to be evaluated ≥ Grade 2 AE Part 2 – Dose Expansion / Optimization (~40 patients) Part 1 – Dose Escalation (~30 patients) Trial status information provided as of June 2, 2025. MTD = maximum tolerated dose; RP2D = recommended Phase 2 dose

CT-95 Program CT-95 Competitive Landscape 28 Clinical Programs – 2nd Generation 1st Generation CT-95 ZW171 AMG-305 HPN-5361 ABBV-4282 Company Context Zymeworks3,4 Amgen5 Harpoon AbbVie Format 2 + 2 2 + 1 1 + 1 + 2 CDH3 + MSLN dBiTE TriTAC 2 + 2 PK Enhancement Fc Fc Truncated Fc Albumin Fc Avoids MSLN sink ✘ ✘ ✘ High potency TCE ✘ ✘ Program Status Phase 1 FPI Apr 2025 Phase 1 FPI Oct. 2024 Phase 1 FPI Oct. 2023 Discontinued Discontinued • 1st generation MSLN T cell engagers (TCE) were discontinued due to a lack of efficacy • Lack of efficacy may have been attributed to lower drug exposure due to binding to shed mesothelin (sMSLN)1,2 1 Harpoon Therapeutics Corporate Presentation, 4 June 2021; 2 Fong, J Immunother Cancer, 2021; 3 Piscitelli, PEGS Boston, 2023; 4 Zymeworks R&D Day, 2022; 5 WO2022096716A2. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Context Therapeutics Inc. - June 2025

CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - June 202529

Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-202 Program 30 Context Therapeutics Inc. - June 2025 Selected Cancer indications Incidence (US Only) R/R Incidence Nectin-4 Positive Nectin-4 Med/High Patient Population Based on R/R Incidence Non-Small Cell Lung 201,229 110,653 64%1 30%1 70,818 Colon 152,810 53,010 87%1 78%1 46,119 Pancreatic 66,440 51,750 71%1 37%1 36,743 Bladder (urothelial) 83,190 20,000 83%1 60%1 16,600 Breast (TNBC) 62,054 15,500 69%1 53%1 10,695 Head and Neck 54,000 12,000 59%1 18%1 7,080 Esophageal 22,370 16,130 55%1 24%2 8,872 Gastric 26,890 12,000 71%3 60%3 8,520 Ovarian 19,900 12,800 57%4 2%4 7,296 Initial indications of interest based on: • Nectin-4 prevalence • Patient population size • Target validation via antibody-drug conjugates (ADCs) Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; Patient population derived from Nectin-4 positive population multiplied by R/R incident population. 1 Challita, Can Res, 2016; 2 Zhang, Oncol Lett, 2018; 3 Derycke, Am J Clin Pathol, 2010; 4 Kobecki, Int J Mol Sci, 2023

CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - June 202531 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal keratinocytes, sweat glands, and hair follicles, Nectin-4 targeted treatments are associated with dermatological side effects • CT-202 uses pH dependent binding to both Nectin-4 and CD3 to minimize binding to healthy tissues and maximize binding and T cell activation within the tumor microenvironment Avidity optimized to mitigate CRS risk • Bivalent Nectin-4 binding to reduce T cell crosslinking in the absence of target • Steric hindrance of CD3 binding by Fc domain prevents T cell crosslinking by single CT-202 molecules Ease of manufacturing • IgG1 backbone is highly stable and enables high yield Anticipated IND filing in mid 2026

Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin CT-202 Program 32 Logic Gating Through pH Dependency + Increased Target Selectivity Through Avidity 1 Chang, PNAS, 2021 CD3 Potent T cell activationNo T cell activation High on-/off-rate when bound to Nectin-4 monomer Avidity-enhanced Nectin-4 binding T cell Tumor 30x gain of activity in acidic tumor microenvironment versus healthy cells1 Context Therapeutics Inc. - June 2025 No CT-202 Binding CT-202 Binding

CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - June 202533 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to enfortumab TCE control antibodies in mice Reduced Cytokine Release CT-202 treatment resulted in significantly lower IL-6 induction compared to enfortumab TCE benchmark antibodies in NHP CT -2 02 En fo rt um ab T CE CT -2 02 En fo rt um ab T CE Control CT-202 1 mg/kg CT-202 0.5 mg/kg CT-202 0.25 mg/kg Control Enfortumab TCE 1 mg/kg Enfortumab TCE 0.5 mg/kg Enfortumab TCE 0.25 mg/kg CT-202 0.1 mg/kg CT-202 1 mg/kg CT-202 5 mg/kg Enfortumab TCE 0.1 mg/kg Enfortumab TCE 1 mg/kg Enfortumab TCE 5 mg/kg Padcev = enfortumab vedotin 30x Higher

CT-202 Program CT-202 Competitive Landscape Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Henlius Asset CT-202 BT74802 RNDO-5643 HLX-309 Format 2 + 2 (pH dependent) 1 + 2 (Bicycle) 1 + 1 (Fixed light chain) n.d. Conditionally active ✘ ✘ n.d. Avidity enhanced ✘ ✘ n.d. Immune Effector CD3 4-1BB CD28 4-1BB Program Status Preclinical (IND filing Mid 2026) Phase 1 (completed) Preclinical (Ph 1 late 2025) Preclinical Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator – BT7480: 2 partial responses out of 33 patients treated in a Phase 1 dose escalation trial, pursuing combination studies going forward1 – RNDO-564: detuning CD28 may limit potency in tumor cells with low or moderate Nectin-4 expression3 1 Bicycle Therapeutics R&D Day, Dec 2023; 2 Hurov, J Immunother Cancer, 2021; 3 PEGS Boston 2024. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Context Therapeutics Inc. - June 202534

Corporate 35 Context Therapeut ics Inc . - June 2025

Corporate Experienced Leadership Team • Experienced management team • Clinical team has developed T cell therapies • Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD1 Chief Medical Officer Context Therapeutics Inc. - June 202536 Jennifer Dashnau, PhD SVP Technical Operations Jennifer Minai Chief Financial Officer Chris Beck, MBA SVP Operations 1 Starting on June 9, 2025.

Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors + ADC Resistance Large Unmet Need Claudin 6 + Mesothelin + Nectin-4 High-Value Targets CTIM-76 initial data 1H 2026 CT-95 initial data Mid 2026 CT-202 IND filing Mid 2026 Anticipated Milestones Deep oncology experience + Focus on clinical execution Strong Team Expected cash runway into 2027 Cash Runway Context Therapeutics Inc. - June 202537

Glossary ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome Fab Fragment antigen-binding region GPI Glycosylphosphatidylinositol IHC Immunohistochemistry IND Investigational new drug IV Intravenous Mabel Minimum anticipated biologic effect level MoA Mechanism of action MSLN Mesothelin MTD Maximum tolerated dose N.D. Not disclosed Context Therapeutics Inc. - June 202539 ORR Overall response rate PFS Progression free survival RP2D Recommended Phase 2 dose TCE T cell engager TRAE Treatment-related adverse event scFv Single chain variable fragment